药康生物
(688046)
| 流通市值：23.76亿 | | | 总市值：47.77亿 |
| 流通股本：2.04亿 | | | 总股本：4.10亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 561,770,887.66 | 560,166,086.8 | 661,697,286.12 | 589,853,706.2 |
| 应收票据及应收账款 | 319,023,850.2 | 269,390,164.86 | 281,444,035.75 | 245,987,387.42 |
| 应收账款 | 319,023,850.2 | 269,390,164.86 | 281,444,035.75 | 245,987,387.42 |
| 预付款项 | 6,214,414.47 | 3,916,097.4 | 7,262,394.67 | 6,366,764.33 |
| 其他应收款合计 | 5,611,547.85 | 6,090,877.19 | 5,417,143.89 | 5,309,197.97 |
| 存货 | 54,367,889.75 | 47,091,812.15 | 52,353,351.43 | 48,232,026.57 |
| 一年内到期的非流动资产 | 120,049,164.25 | 120,104,383.16 | 76,576,766.82 | 75,916,383.24 |
| 其他流动资产 | 14,847,941.72 | 13,039,455.16 | 15,649,663.52 | 6,745,621.04 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,648,107,709.6 | 1,657,522,891.61 | 1,627,275,575.63 | 1,599,838,790.55 |
| 非流动资产: | | | | |
| 债权投资 | 3,026,093.9 | - | - | - |
| 长期股权投资 | 69,261,498.3 | 69,197,723.04 | 68,995,195.9 | 69,038,210.85 |
| 其他权益工具投资 | 500,000 | 500,000 | - | - |
| 固定资产 | 495,193,089.6 | 486,698,719.29 | 204,878,907.13 | 194,173,091.58 |
| 在建工程 | 97,072,000.09 | 89,603,382.15 | 258,926,729.41 | 231,839,410.7 |
| 生产性生物资产 | 7,469,083.49 | 5,975,977.77 | 7,252,356.23 | 5,130,700.98 |
| 使用权资产 | 44,462,941.84 | 42,617,877.74 | 41,501,232.01 | 40,310,394 |
| 无形资产 | 47,826,932.47 | 47,340,785.94 | 47,467,423.13 | 47,361,029.64 |
| 长期待摊费用 | 34,047,980.14 | 36,682,330.28 | 14,993,013.04 | 15,616,885.06 |
| 递延所得税资产 | 36,492,271.96 | 31,852,390.65 | 19,857,804.19 | 18,484,203.28 |
| 其他非流动资产 | 75,971,896.11 | 109,597,800.1 | 186,942,560.35 | 178,504,918.7 |
| 非流动资产平衡项目 | 0 | 0.01 | 0.01 | 0 |
| 非流动资产合计 | 911,323,787.9 | 920,066,986.97 | 850,815,221.4 | 800,458,844.79 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,559,431,497.5 | 2,577,589,878.58 | 2,478,090,797.03 | 2,400,297,635.34 |
| 流动负债: | | | | |
| 短期借款 | 85,154,000.44 | 76,157,041.99 | 77,041,439.3 | 47,170,672.02 |
| 应付票据及应付账款 | 89,471,249.26 | 101,859,659.33 | 64,081,875.6 | 57,028,275.22 |
| 应付账款 | 89,471,249.26 | 101,859,659.33 | 64,081,875.6 | 57,028,275.22 |
| 合同负债 | 103,060,615.19 | 108,419,700.44 | 98,506,720.56 | 89,165,529.23 |
| 应付职工薪酬 | 27,921,915.7 | 43,676,136.5 | 44,679,518.45 | 36,647,140.81 |
| 应交税费 | 15,178,958.6 | 16,663,623.33 | 6,302,018.51 | 4,722,767.17 |
| 其他应付款合计 | 9,504,832.78 | 10,237,247.62 | 8,342,831.48 | 27,231,644.33 |
| 应付股利 | - | - | - | 16,810,000 |
| 一年内到期的非流动负债 | 10,481,343.41 | 9,395,662.61 | 8,684,599.44 | 6,395,525.03 |
| 流动负债平衡项目 | 0.01 | 0.01 | 0 | 0 |
| 流动负债合计 | 340,772,915.39 | 366,409,071.83 | 307,639,003.34 | 268,361,553.81 |
| 非流动负债: | | | | |
| 租赁负债 | 38,341,193.58 | 36,070,908.5 | 36,141,920.4 | 36,563,293.91 |
| 递延收益 | 39,371,350.72 | 41,044,220.63 | 39,621,622.22 | 41,962,992.14 |
| 递延所得税负债 | 9,718,029.64 | 9,409,233.3 | 11,795,642.43 | 10,437,796.58 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 87,430,573.94 | 86,524,362.43 | 87,559,185.05 | 88,964,082.63 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 428,203,489.33 | 452,933,434.26 | 395,198,188.39 | 357,325,636.44 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 410,000,000 | 410,000,000 | 410,000,000 | 410,000,000 |
| 资本公积 | 1,259,054,132.56 | 1,258,166,782.15 | 1,257,402,651.87 | 1,257,539,117.91 |
| 减:库存股 | 23,869,236.73 | - | - | - |
| 其他综合收益 | 1,159,453.95 | 1,085,407.95 | 1,307,576.07 | 1,396,036.24 |
| 盈余公积 | 43,553,007.48 | 43,553,007.48 | 32,313,137.84 | 32,313,137.84 |
| 未分配利润 | 441,330,650.91 | 411,851,246.74 | 381,869,242.85 | 341,723,706.91 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,131,228,008.17 | 2,124,656,444.32 | 2,082,892,608.63 | 2,042,971,998.9 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,131,228,008.17 | 2,124,656,444.32 | 2,082,892,608.63 | 2,042,971,998.9 |
| 负债和股东权益合计 | 2,559,431,497.5 | 2,577,589,878.58 | 2,478,090,797.03 | 2,400,297,635.34 |
| 公告日期 | 2024-04-27 | 2024-04-27 | 2023-10-28 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |